Annual Report 2006 - Boehringer Ingelheim

More documents

Recommendations

Info

Boehringer Ingelheim’s shareholders have set the course for the future in such a way that we can continue to build on the successful development of recent years as an independent company. This applies not only to the corporate strategy decided jointly with the Board of Managing Directors, but also to the make-up of both the Board and the Shareholders’ Committee. After 32 years of highly successful commitment to Boehringer Ingelheim, as Chairman of the Board of Managing Directors, and since 2001 as Chairman of the Shareholders’ Committee too, Dr Heribert Johann took well deserved retirement as of 31 December 2006. Dr Johann played a key role in shaping our company’s strategic development over the past 15 years and we are profoundly grateful to him for his unflagging commitment to Boehringer Ingelheim. The commitment of the owner-family to Boehringer Ingelheim, meanwhile, has been further strengthened by two important decisions taken in 2006: the move of family member Hubertus von Baumbach to the Board of Managing Directors at the beginning of 2009 and the increased involvement of other family members in the Shareholders’ Committee, which is now chaired again by a family member representing the increased commitment of the fourth generation of shareholders. Christian Boehringer, Chairman of the Shareholders’ Committee We are confident of the continued motivation and loyalty of our employees, the expertise and experience of the Board and constructive commitment of our Advisory Board in the future. On behalf of the shareholders of Boehringer Ingelheim, allow me to congratulate all those I have mentioned on the very successful financial year 2006. Thank you all for your tremendous efforts. We look forward to continuing to work closely with our employees, the Board of Managing Directors and the Advisory Board for the good of Boehringer Ingelheim as a whole. Despite what is sometimes a difficult economic and political environment, and some highly competitive markets, we are confident that we are set to remain one of the world’s leading pharmaceutical companies. Christian Boehringer Chairman of the Shareholders’ Committee The Shareholders’ Perspective
Key Aspects of 2006 2006 was again a rewarding year for Boehringer Ingelheim. We grew faster than the market average for the seventh year in succession. While the global pharmaceutical markets are changing and mergers and consolidation efforts continue, we again maintained our successful course as an independent and dynamically growing pharmaceutical company. We are proud that we once again achieved our overall goal of helping people by making our medications available to patients through researching and developing new and innovative drugs. Our economic success in recent years mirrors the value of our medications for patients. Market analyses by the healthcare information provider IMS confirm that our +8.4 % growth rate was appreciably healthier than that of the pharmaceutical market in general (+6.1 %). Although our growth curve flattened out as a result of the generic competition that our antirheumatic drug mobic® has been facing in the USA since summer 2006, we increased our market share in 2006 worldwide and in the USA to about 2 %. Overall, we are happy with our 2006 results. Boehringer Ingelheim A n n u A l R e p o R t 2 0 0 6 Success in serving patients Boehringer Ingelheim is a pharmaceutical company that generates almost 80 % of its net sales with prescription medicines. Yet we do not measure our success in financial key figures alone, but also, and of equal importance, in terms of the acceptance of our products and programmes. For instance, in conjunction with our donation programme for the anti-AIDS product viramune®, we have so far succeeded in providing medication for almost 1 million mother-child pairs in around 60 countries for the prevention of mother-to-child transmission of HIV. About six million patients benefited from our product spiriva® for chronic obstructive pulmonary disease (COPD). The number of patients using our anti-hypertension medicine micardis® amounted to more than four million in 2006. Value through Innovation Naturally, the success of our products is reflected in our business results. In 2006, our net sales across all business areas grew by 11 % to almost EUR 10.6 billion. We were also pleased that we were able to increase the number of our employees by 3 % to 38,428 and so offer more than 1,000 new and qualified jobs around the world.
Page 1 and 2: Value through Innovation Annual Rep
Page 3 and 4: Contents 1 Value Through Innovation
Page 5: The Shareholders’ Perspective Dea
Page 9 and 10: This growth was clearly restrained
Page 11 and 12: Shareholders’ Committee Dr Heribe
Page 13 and 14: “There is help” “The woman wh
Page 15 and 16: 1 continued from page 10 A Kenyan m
Page 17 and 18: 1 Our people In pursuing our vision
Page 19 and 20: Company childcare enters new territ
Page 21 and 22: 1 Caring for our neighbours We are
Page 23 and 24: 0 Children from St Margaret Clither
Page 25 and 26: Our environment & employee safety A
Page 27 and 28: thanks to the use of the wood-fired
Page 29 and 30: Our goals We shall continue to inve
Page 31 and 32: Targeting tomorrow’s therapies Th
Page 33 and 34: 0 continued from page 28 “Boehrin
Page 35 and 36: Our R & D strategy Research and dev
Page 37 and 38: Ridgefield, USA Cardiovascular, imm
Page 39 and 40: Vienna, Austria Oncology Boehringer
Page 41 and 42: Our expertise in landmark studies L
Page 43 and 44: From mind to man - the R & D proces
Page 45 and 46: New biological entities (NBE) One o
Page 47 and 48: The development of our businesses W
Page 49: Rin Fujima, Kyoto, Japan, suffers f
Page 52 and 53: Human Pharmaceuticals Branded presc
Page 54 and 55: cal exercise capacity and the reduc
Page 56 and 57:
“Like a great round of golf“
Page 58 and 59:
gives patients a better chance of g
Page 60 and 61:
aptivus® was launched in the USA i
Page 62 and 63:
enzymes, such as the HCV serine pro
Page 64 and 65:
Børge Madsen, Copenhagen, Denmark.
Page 66 and 67:
Cardiovascular diseases Despite sig
Page 68 and 69:
actilyse® is the first and only th
Page 70 and 71:
fibrillation in some 40 countries i
Page 72 and 73:
Treatment modalities used to reliev
Page 74 and 75:
HuCAL antibody directed against a c
Page 76 and 77:
hand, the end of exclusivity in Eur
Page 78 and 79:
Generic Prescription Medicines The
Page 80 and 81:
Ben Venue - a world leader in steri
Page 82 and 83:
Mara Lovera, Buenos Aires, Argentin
Page 84 and 85:
Consumer Health Care Our Consumer H
Page 86 and 87:
Switching reinforces the trend towa
Page 88 and 89:
Alexander (left) and Christopher pl
Page 90 and 91:
Animal Health The sound progress of
Page 92 and 93:
located, trained and placed with fi
Page 94 and 95:
Our Customer Orientation Our custom
Page 96 and 97:
On a biopharmaceutical compound’s
Page 98 and 99:
Pharmaceuticals Production Our Phar
Page 100 and 101:
Counterfeits - a real threat for pa
Page 102 and 103:
Group Management Report 2006
Page 104 and 105:
companies lost their patent protect
Page 106 and 107:
To summarise, we see the success of
Page 108 and 109:
Production Production sites belongi
Page 110 and 111:
In the area of HIV/AIDS therapy, we
Page 112 and 113:
only 2 %. The region’s overall ne
Page 114 and 115:
of the cash flow, which rose by EUR
Page 116 and 117:
Report on expected developments The
Page 118 and 119:
Consolidated Financial Statements 2
Page 120 and 121:
C. H. Boehringer Sohn Grundstücksv
Page 122 and 123:
C. H. Boehringer Sohn, Ingelheim Co
Page 124 and 125:
C. H. Boehringer Sohn, Ingelheim St
Page 126 and 127:
The following subsidiaries were exe
Page 128 and 129:
2 Accounting and evaluation methods
Page 130 and 131:
3 Notes to the consolidated balance
Page 132 and 133:
3.3 Financial assets (in millions o
Page 134 and 135:
Pension provisions Boehringer Ingel
Page 136 and 137:
4 Notes to the consolidated profit
Page 138 and 139:
4.7 Holding income (in millions of
Page 140 and 141:
Other mandatory disclosures accordi
Page 142 and 143:
Derivative financial instruments at
Page 144 and 145:
With the following exception, our a
Page 146 and 147:
Product name Active ingredient Indi
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Comparison of Balance Sheets/ Finan
show all

Annual Report 2006 - Boehringer Ingelheim

Create successful ePaper yourself

Delete template?

Save as template?